Health
FDA authorizes marketing of new device for short-term treatment of gait deficit in MS patients – News-Medical.Net
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate…
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that consists of a non-implantable apparatus…
-
Noosa News17 hours agoFollowing Up Hottest 100 of Australian Songs Success with a Second Documentary About Your Life and Career: Jimmy Barnes Talks ‘Working Class Man’
-
Noosa News22 hours agoItalian Film Festival, Brisbane: All the Details
-
Noosa News17 hours agoKatter and pregnant wife crash-land plane in outback Qld
-
Business23 hours ago7% lift in profits and guidance upgrade